PMID- 22261336
OWN - NLM
STAT- MEDLINE
DCOM- 20120427
LR  - 20211216
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 319
IP  - 1
DP  - 2012 Jun 1
TI  - mTOR inhibitors in cancer therapy.
PG  - 1-7
LID - 10.1016/j.canlet.2012.01.005 [doi]
AB  - The mammalian target of rapamycin (mTOR) plays a key role in regulation of 
      cellular metabolism, growth, and proliferation. The frequent hyperactivation of 
      mTOR signaling makes it an attractive target for therapeutic intervention and has 
      driven the development of a number of mTOR inhibitors. Encouraging data from 
      preclinical studies have resulted in initiation of multiple clinical trials. 
      Furthermore, combinational strategies are being studied in an effort to overcome 
      resistance and enhance efficacy. Although additional studies are required to 
      determine their specific role in the clinical setting, mTOR inhibitors remain a 
      promising therapeutic option for the treatment of cancer.
CI  - Copyright (c) 2012 Elsevier Ireland Ltd. All rights reserved.
FAU - Zaytseva, Yekaterina Y
AU  - Zaytseva YY
AD  - Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA.
FAU - Valentino, Joseph D
AU  - Valentino JD
FAU - Gulhati, Pat
AU  - Gulhati P
FAU - Evers, B Mark
AU  - Evers BM
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120117
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Neoplasms/*drug therapy/metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/physiology
EDAT- 2012/01/21 06:00
MHDA- 2012/04/28 06:00
CRDT- 2012/01/21 06:00
PHST- 2011/11/09 00:00 [received]
PHST- 2011/12/22 00:00 [revised]
PHST- 2012/01/10 00:00 [accepted]
PHST- 2012/01/21 06:00 [entrez]
PHST- 2012/01/21 06:00 [pubmed]
PHST- 2012/04/28 06:00 [medline]
AID - S0304-3835(12)00030-4 [pii]
AID - 10.1016/j.canlet.2012.01.005 [doi]
PST - ppublish
SO  - Cancer Lett. 2012 Jun 1;319(1):1-7. doi: 10.1016/j.canlet.2012.01.005. Epub 2012 
      Jan 17.